Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- Therapeutic
- Pharmaceuticals
- Disease
- DNA
- Proteins
- Assay
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27362
License Grant
In 1983, the Company acquired the exclusive worldwide rights to patented IL-2 compounds, compositions and other processes and other lymphokine – related compounds, compositions and processes one of which is sometimes referred to as Multikinetm, or buffy-coat interleukins, which is a combination, or cocktail of IL-2 and certain lymphokines and cytokines. Multikine is a natural mixture of human immune system regulators called cytokines, including Interleukin-2 and others. Several are being investigated individually as potential HIV-1 and cancer treatments.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 26784
License Grant
The Licensee will receive the exclusive right to market, distribute and sell the Products in the Territory. If Licensee has not enrolled at least 20 patients in a controlled, mutually designed head & neck cancer clinical trial by June 1, 2004, they will lose the exclusive right to market, distribute and sell the Products in the Territory. Licensee may market, sell and/or distribute the Products under the trademark owned or used by the Company (e.g. Multikine(TM)).
License Property
MultikineTM is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines including Interleukins, interferons, chemokines and colony-stimulating factors. As a neo-adjuvant, Multikine has induced tumor reduction and tumor necrosis in Phase II trials of head & neck cancer. Multikine is nontoxic and offers a diverse and possibly synergistic cytokine profile believed to play an important role in local and regional and possible systemic immune restoration.
MULTIKINE(R) is manufactured using proprietary cell culture technologies, is a combination, or 'cocktail', of natural human interleukin-2 ('IL-2') and certain lymphokines and cytokines. MULTIKINE is being tested to determine if it is effective in improving the immune response of cancer patients.
Field of Use
Multikine appears to boost the patient’s immune system and break tumor tolerance. The CEL-1000 is a peptide that has been shown to provide protection in animals against malaria, herpes and cancer.
IPSCIO Record ID: 328902
License Grant
Pursuant to the License Agreement, as amended, the University Research Association licensed the exclusive worldwide rights to certain patents on IRX-2 in exchange for royalties.
License Property
IRX-2, a novel cytokine-based therapy, to treat patients with cancer. IRX-2 active constituents, namely Interleukin-2 (IL-2) and other key cytokines are postulated to signal, enhance and restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells.
IRX-2 is an allogeneic, reproducible, primary, cell-derived biologic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as a subcutaneous injection around lymph node beds.
Field of Use
Field of use is for the treatment of cancer.
IPSCIO Record ID: 26159
License Grant
The Licensee, a specialty pharmaceutical company focused on the development of pharmaceutical products for the treatment of cancer and pain entered into a royalty Agreement with a doctor, the Licensor, under which the Licensee has an exclusive License to certain patents for Ceplene (histamine dihydrochloride or any other H2 receptor agonist) configured for the systemic treatment of cancer, infectious diseases, autoimmune diseases and other medical conditions.
License Property
Ceplene (histamine dihydrochloride) is the Licensee's lead oncology compound, administered in conjunction with low dose interleukin-2 (IL-2), for the maintenance of first remission in patients with Acute Myeloid Leukemia (AML).
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 211947
License Grant
Licensor grants to Swiss Licensee under the Licensor Patent Rights and PEG Patent Rights a nonexclusive, nontransferable license and sublicense within the Non-Subsidiary of Licensor Territory, with no right to grant sublicenses to others, to make, have made, use or sell only Licensed Licensee IL-2 Product and Licensed PEG IL-2 Product.
License Property
The Licensor Patent Rights means those patents and patent applications relating to human recombinant interleukin-2.
The Licensor PEG Patent Rights means those patents and patent applications directed to the conjugation of interleukin-2 to a water soluble polymer selected from polyethylene glycol homopolymers or polyoxyethylated polyols.
The Licensed Licensee IL-2 Product means any product, including hybrids, conjugates and formulations, containing, by molecular combination or admixture, Roche IL-2 as the only interleukin-2 ingredient, the manufacture, use or sale thereof.
The Licensed Licensee PEG IL-2 Product means any product, including hybrids, conjugates and formulations, containing, by molecular combination or admixture, licensee IL-2 as the only interleukin-2 ingredient, the manufacture, use or sale thereof.
Field of Use
Licensee is active in the field of producing and clinically testing interleukin-2, in particular utilizing recombinant DNA methods to provide an interleukin-2 molecule having an amino acid sequence thought to be the same as native human interleukin-2 except for an optional N-terminal methionine which may or may not be present in the recombinant compound.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
